Combined treatment with alendronate plus, alfacalcidol in established postmenopausal or male osteoporosis: A prospective, randomised controlled trial.

被引：0

作者：

Ringe, J. D.

Faber, H.

Fahramand, P.

Dorst, A.

Schacht, E.

机构：

[1] Univ Cologne, Med Klin 4, Klinikum Leverkusen, Leverkusen, Germany

[2] ZORG Zurich Osteoporosis Res Grp, Zollikerberg, Switzerland

来源：

JOURNAL OF BONE AND MINERAL RESEARCH | 2006年 / 21卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：S308 / S309

页数：2

共 50 条

[1] Superiority of a combined treatment of Alendronate and Alfacalcidol compared to the combination of Alendronate and plain vitamin D or Alfacalcidol alone in established postmenopausal or male osteoporosis (AAC-Trial)
Ringe, J. D.
Farahmand, P.
Schacht, E.
Rozehnal, A.
[J]. RHEUMATOLOGY INTERNATIONAL, 2007, 27 (05) : 425 - 434
[2] Superiority of a combined treatment of Alendronate and Alfacalcidol compared to the combination of Alendronate and plain vitamin D or Alfacalcidol alone in established postmenopausal or male osteoporosis (AAC-Trial)
J. D. Ringe
P. Farahmand
E. Schacht
A. Rozehnal
[J]. Rheumatology International, 2007, 27 : 425 - 434
[3] COMBINED ALFACALCIDOL AND ALENDRONATE THERAPY IS SUPERIOR TO THE RESPECTIVE MONOTHERAPIES IN ESTABLISHED POSTMENOPAUSAL OR MALE OSTEOPOROSIS
Ringe, J. D.
Farahmand, P.
[J]. OSTEOPOROSIS INTERNATIONAL, 2019, 30 : S397 - S397
[4] Superiority of a combined treatment of alfacalcidol and alendronate compared to the monotherapies in postmenopausal osteoporosis
不详
[J]. CALCIFIED TISSUE INTERNATIONAL, 2006, 78 : S151 - S151
[5] Superiority of a combined treatment of alfacalcidol and alendronate compared to the monotherapies in postmenopausal osteoporosis
Ones, K.
Schacht, E.
[J]. OSTEOPOROSIS INTERNATIONAL, 2006, 17 : S20 - S20
[6] Superiority of a combined treatment of alfacalcidol and alendronate compared to the respective monotherapies in established osteoporosis
Ringe, J. D.
Farahmand, P.
Schacht, E.
[J]. OSTEOPOROSIS INTERNATIONAL, 2006, 17 : S238 - S238
[7] Treatment of renal transplant recipients with low bone mineral density: A randomized prospective trial of alendronate, alfacalcidol, and alendronate combined with alfacalcidol
Trabulus, S.
Altiparmak, M. R.
Apaydin, S.
Serdengecti, K.
Sariyar, M.
[J]. TRANSPLANTATION PROCEEDINGS, 2008, 40 (01) : 160 - 166
[8] COMBINED OSTEOPOROSIS TREATMENT WITH ANTIRESORPTIVE ALENDRONATE PLUS PLEIOTROPICALLY ACTING ALFACALCIDOL: RATIONALE AND CLINICAL EVIDENCE
Ringe, J.
Schacht, E.
[J]. OSTEOPOROSIS INTERNATIONAL, 2009, 20 : 39 - 39
[9] Antifracture efficacy of combined treatment with alendronate and alfacalcidol for osteoporosis in early-phase treatment
Miyakoshi, N.
Kasukawa, Y.
Kodama, H.
Noguchi, H.
Sasaki, H.
Kamo, K.
Shimada, Y.
[J]. JOURNAL OF BONE AND MINERAL RESEARCH, 2007, 22 : S341 - S341
[10] EFFECTS OF A COMBINED TREATMENT WITH ALFACALCIDOL AND ALENDRONATE VERSUS TREATMENT WITH ALENDRONATE ALONE ON BONE MINERAL DENSITY AT LUMBAR SPINE AND TOTAL HIP IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS OR OSTEOPENIA
Bock, O.
Felsenberg, D.
Boerst, H.
Degner, C.
Armbrecht, G.
Schacht, E.
Mazor, Z.
Hashimoto, J.
Martus, P.
Runge, M.
[J]. OSTEOPOROSIS INTERNATIONAL, 2009, 20 : 76 - 77

← 1 2 3 4 5 →